In Brief: Roche Xeloda
Executive Summary
Roche Xeloda: FDA's Oncologic Drugs Advisory Committee will discuss Roche's capecitabine on the afternoon of March 19 for treatment of locally advanced or metastatic breast cancer after failure of paclitaxel and an anthracycline-containing regimen. During the morning session that day, the committee will review a supplement for Lilly's Gemzar (gemcitabine) as a single agent or in combination with cisplatin for first-line treatment of locally advanced or metastatic NSCLC. The meetings begin each day at 8 a.m. at the Bethesda, Md. Holiday Inn...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth